.png)
Our Research
Research is at the heart of Chromodiversity’s mission to transform how the world understands and supports genetic and developmental differences. By exploring new ways to describe, measure, and respond to diversity in human development, we aim to move beyond outdated, deficit-based models toward more inclusive and empowering approaches.
Read about our 'Depathologizing the Language of Genetics' research.
From Deficit to Difference
Our foundation, in collaboration with Children’s Hospital Colorado (USA), Murdoch Children’s Research Institute (Australia) and SEHA (UAE), is advancing Chromodiversity Compass™: a next-generation digital health platform that integrates genetic data, neurodevelopmental screening, and coordinated care. Our goal is to improve outcomes for children and adults with genetic and neurodevelopmental differences through data-driven, personalized healthcare.
Purpose
Globally, 5–17% of individuals are affected by genetic differences that often remain undiagnosed or unsupported. This leads to delayed intervention and avoidable long-term health and economic burdens. Current systems lack scalable, coordinated care and robust data to understand how genetic variations influence neurocognitive conditions such as autism, ADHD, and dyslexia. As a result, opportunities for early intervention and prevention are missed, increasing costs for families and healthcare systems.
Unmet Needs
ChromoCompass™ is a family-centered platform designed for developmental tracking, actionable clinical insights, and personalized support. Its AI-powered analytics enable large-scale, frequent data collection and deep cohort analysis at a fraction of the cost of traditional in-person evaluations. This provides families, clinicians, and researchers with unprecedented insight into the relationship between genomics and neurodevelopment.
Innovation and Value
The platform has been beta-tested with 93 families across 15 countries, receiving strong caregiver endorsements. Comparative pilots with Children’s Hospital Colorado and SEHA, along with a longitudinal study with the Australian Epi-Genomic Newborn Screening (EpiGNs) program, will begin in 2025–2026 to further validate outcomes.
Proven Impact